Author’s Response to: Nebulised Heparin for Lung Disease: Three Overlooked Risks that Merit Study Before Chronic Clinical Use

Margarid Miranda; Marc Brown; Frank MP van Haren; Bethany Brown; Clive Page

doi:10.1007/s00408-026-00938-3

Enriched record

Author’s Response to: Nebulised Heparin for Lung Disease: Three Overlooked Risks that Merit Study Before Chronic Clinical Use

Margarid Miranda, Marc Brown, Frank MP van Haren, Bethany Brown, Clive Page

Lung2026doi:10.1007/s00408-026-00938-3

Citation graph

Abstract

No public abstract is available from the verified source records.

Authors

Margarid Miranda#1 Marc Brown#2 Frank MP van Haren#3 Bethany Brown#4 Clive Page#5

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

pubmed

Confidence 98%

europepmc

Confidence 96%

unpaywall

Confidence 95%

datacite

Referenced works

View all references →

Nebulised Heparin for Lung Disease: Three Overlooked Risks that Merit Study Before Chronic Clinical Use

2026 · 0 citations

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

10.1007/s00408-026-00937-4

10.1007/s00408-026-00905-y

10.1007/s00408-026-00905-y · 2026

10.1124/pharmrev.122.000684

10.1124/pharmrev.122.000684 · 2023

10.1128/aac.20.2.155

10.1128/aac.20.2.155 · 1981

10.1186/s40168-017-0265-7

10.1186/s40168-017-0265-7 · 2017

10.1186/s12931-019-1078-y

10.1186/s12931-019-1078-y · 2019

10.1183/09031936.06.00069005

10.1183/09031936.06.00069005 · 2006

10.1183/09031936.01.17100360

10.1183/09031936.01.17100360 · 2000

10.1056/nejmoa1104623

10.1056/nejmoa1104623 · 2011

10.1038/s41598-023-40489-8

10.1038/s41598-023-40489-8 · 2023

10.1183/13993003.congress-2025.rct2287

Author’s Response to: Nebulised Heparin for Lung Disease: Three Overlooked Risks that Merit Study Before Chronic Clinical Use

Referenced works

Cited by

External reference records

Additional external references